1.HIV infections – drug therapy. 2.Anti-HIV agents – adverse effects. 3.Anti-retroviral agents. 4.Benzoxazines – adverse effects. 5.Pregnancy. 6.Disease transmission, Vertical - prevention and control. 7.Treatment outcome. I.World Health Organization
A Global Inventory of Alternative Medical Waste Treatment Technologies
A Joint Statement by the World Health Organization and the United Nations Children’s Fund.
Available in different languages: English, French, Arabic, Russian
HIV & AIDS Treatment in Practice No. 188
HIV & AIDS Treatment in Practice no. 201
Weekly epidemiological record / Relevé épidémiologique hebdomadaire
22 SEPTEMBER 2017, 92th YEAR / 22 SEPTEMBRE 2017, 92e ANNÉE
No 38, 2017, 92, 557–572
There are 4 main forms of the disease: visceral leishmaniasis (VL, also known as kala-azar); post-kala-azar dermal leishmania...sis (PKDL); cutaneous leishmaniasis (CL); and mucocutaneous leishmaniasis (MCL). While cutaneous leishmaniasis is the most common form of the disease, visceral leishmaniasis is the most serious and can be fatal if untreated. Additionally, leishmaniasis can be classified as anthroponotic or zoonotic depending on whether the natural reservoir of the parasite is human or animal.
This report updates global epidemiological information on VL and CL to 2015, based on the main indicators published in the GHO, as of 1st September 2017.
more
For several decades, civil society organisations (CSOs) in Nigeria have been advocating for increased resources for family planning (FP) and reproductive health (RH) services and commodities. To help CSOs in Nigeria understand and actively participate in the budget process at the state level, a team... from the Health Policy Project conducted an assessment to identify the differences between theory and practice in state-level budgeting. The team selected two states—Cross River and Zamfara—and compiled information on their budget process for the health sector.
more
A handbook for leaders and managers
These consolidated guidelines on HIV testing services (HTS) bring together existing and new guidance on HTS across different settings and populations.
The World Health Organization (WHO) first released consolidated guidelines on HTS in 2015, in response to requests from Member States, national pr...ogramme managers and health workers for support to achieve the United Nations (UN) 90–90–90 global HIV targets – and specifically the first target of diagnosing 90% of all people with HIV. In 2016, based on new evidence, WHO released a supplement to address important new HIV testing approaches – HIV self-testing (HIVST) and provider-assisted referral.
Since the release of 2015 and 2016 HTS guidelines, new issues and more evidence have emerged. To address this, WHO has updated guidance on HIV testing services. In this guideline, WHO updates recommendation on HIVST and provides new recommendations on social network-based HIV testing approaches and western blotting (see box, next page). This guideline seeks to provide support to Member States, programme managers, health workers and other stakeholders seeking to achieve national and international goals to end the HIV epidemic as a public health threat by 2030.
These guidelines also provide operational guidance on HTS demand creation and messaging; implementation considerations for priority populations; HIV testing strategies for diagnosis HIV; optimizing the use of dual HIV/syphilis rapid diagnostic tests; and considerations for strategic planning and rationalizing resources such as optimal time points for maternal retesting
more
BMC Family Practice201415:165, DOI: 10.1186/1471-2296-15-165
Open Access